Atherosclerosis and Cardiovascular Diseases

Evaluation of the clinical significance of the discovery of the LDL receptor.- 1. Evaluation of the clinical significance of the discovery of the LDL receptor.- Social aspects of atherosclerosis.- 2. Social aspects of atherosclerosis.- Primary and secondary prevention of atherosclerosis and coronary heart disease.- 3. Primary and secondary prevention of atherosclerosis and coronary heart disease.- The “CNR Progetto Finalizzato Obiettivo 44 Progressione e/o regression” an update on studies in Italy.- 4. The “CNR Progetto Finalizzato Obiettivo 44 Progressione e/o regression” an update on studies in Italy.- Atherosclerosis and the “CNR Progetto Finalizzato Medicina Preventiva e Riabilitativa”.- 5. Atherosclerosis and the “CNR Progetto Finalizzato Medicina Preventiva e Riabilitativa”.- Cardiac and vascular surgery: results, perspectives and hopes.- 6. Cardiac and vascular surgery: results, perspectives and hopes.- Apoproteins - Clinical Aspects.- 7. Genetic basis of apolipoprotein disorders.- 8. Apolipoproteins in differential diagnosis of patients at high risk for atherosclerosis.- 9. Genetic and non-genetic control of apoprotein metabolism in cultured human cells.- 10. The plasma metabolism of apolipoprotein A-IV.- 11. Modified LDL in humans.- 12. Clinical aspects of lipoprotein disorders.- Fixed Versus Dynamic Stenosis: Possible Causes and Therapeutic Approaches.- 13. Fixed versus dynamic stenosis: possible causes and therapeutic approach.- 14. The epicardial coronary arteries at necropsy in acute myocardial infarction.- 15. Perspectives in the management of acute myocardial infarction.- 16. Atherosclerosis and ischaemic heart disease: surgical solutions.- Present Knowledge and Perspectives of Calcium Entry Blockers in the Management of Coronary Artery Disease.- 17. Effects of calcium antagonists and adrenergic antihypertensive drugs on cellular cholesterol metabolism.- 18. Blood platelets: their role in atherogenesis and arterial thrombosis and their inhibition, in particular by calcium antagonists.- Primary and Secondary Prevention: Different Experiences.- 19. Prevention of coronary heart disease - links with other chronic disorders.- 20. Therapy versus prevention of coronary heart disease.- 21. Prevention in Europe - facts, fallacies and future.- 22. Low linoleic acid - a new risk factor for coronary heart disease.- 23. The US National Cholesterol Education Program.- 24. The WHO European Multifactor Preventive Trial of CHD.- 25. Epidemiology and clinical features of hypertension in the elderly.- 26. Atherosclerosis precursors in children. The Bologna study. Preliminary data.- 27. From observational to intervention programmes. The Brisighella study.- Lipid Regulation in the Prevention of Coronary Heart Disease.- 28. Relationship of glucose intolerance and elevated triglyceride: implications for gemfibrozil.- 29. A comparison of different formulations and dosage administrations of gemfibrozil in types IIA and IIB hyperlipidemia.- 30. Coronary heart disease in Italy.- Diet: A Risk Factor and a Means of Prevention of Atherosclerosis and Coronary Heart Disease.- 31. Dietary fiber and lipid metabolism.- 32. Dietary and biochemical studies with textured soy proteins.- 33. Fats from marine animals in human nutrition and prevention of cardiovascular diseases.- 34. The influence of diet and drugs of cholesterol metabolism in the liver.- 35. Individuality of the response of serum cholesterol to dietary cholesterol.- 36. Familial hypercholesterolemia in Italy; plasma cholesterol evaluation and diagnostic insight.- Extra Coronary Atherosclerotic Vascular Diseases.- 37. Do atherosclerotic plaques regress spontaneously in humans?.- 38. Pathogenetic mechanisms of transient brain ischaemic attacks.- 39. Interrelations between the degree of lipid lowering effect and the rate of progression of atherosclerotic cardiovascular disease.- 40. Results of carotid endarterectomy.- New Technologies and New Diagnostic and Therapeutic Approaches to Cardiovascular Diseases.- 41. Haemostatic factors and lipoproteins in atherogenesis.- 42. Comparative evaluation of echographic and histomorphometric data of carotid endarterectomy samples.- 43. Correlative electron microscopy in the study of atherosclerosis.- 44. The role of oxygen free radicals in the ischaemia - reperfusion injury.- 45. Local and remote effects of acute ischaemic infarction on cerebral glucose metabolism in man.- Serotonin and the Cardiovascular System.- 46. Serotonin and cardiovascular disease.- 47. Ketanserin in the treatment of hypertension: clinical review.- 48. Platelets and platelet-related substances in the natural history of atherosclerosis. The role of serotonin.- 49. Prevalence and incidence of leg ischaemia in the general population.- Endogenous Opioids.- 50. Dynorphin-related peptides in central and peripheral tissues: distribution and possible functions.- 51. Aging brain and dementia: change in central opioids and ACTH.- 52. Relationship between endogenous opioids and the cardiovascular system: dynorphin measurement in the human heart: ß-endorphin plasmatic levels assay during acute pulmonary oedema.- Bezafibrate, Atherosclerosis and Ischaemic Heart Disease.- 53. Studies on DNA fragment length polymorphism of human apolipoprotein B gene.- 54. Porphyrins, tumors and atherosclerosis.- 55. Influence of physical exercise on plasma lipoprotein pattern in healthy subjects.- 56. Long-term experience with bezafibrate in different types of hyperlipidemia.- 57. Role of fibrinogen in atherosclerosis: therapeutic effects of bezafibrate in short-term treatment.- Nicotinic Acid Derivatives, Atherosclerosis and Ischaemic Heart Disease.- 58. Effects of Acipimox on in vivo insulin sensitivity in obese subjects and NID diabetics.- 59. The lipid-lowering effect of the acipimox: comparison with tiadenol and probucol.- 60. A controlled trial on the hypolipidemic effect of Acipimox in type IIA and IIB hyperlipoproteinemia.- 61. Effect of Acipimox on serum lipids and apoproteins in type II hyperlipoproteinemia.- 62. Long-term multicentre trial with acipimox in diabetic patients with hyperlipoproteinemia.- Acetylcarnitine and Ageing Brain Syndromes.- 63. Experimental pharmacological aspects in brain aging.- 64. Acute effects of L-acetylcarnetine (LAC) on quantitative EEG (QEEG) and visual evoked potentials (VEPS) in patients affected by senile, presenile and alcoholic dementia. Comparison with L-carnetine.- 65. The pharmacology of cognitive disturbances: problems and perspectives.- 66. L-Acetylcarnetine prevents the parkinsonian syndrome induced by MPTP in monkeys.- Non-Invasive Investigations of the Cardiovascular System.- 67. Nuclear magnetic resonance in the detection of the atherosclerotic lesion.- 68. Perspective and limits of emission tomography in cerebrovascular disorders.- 69. The real utility of nuclear magnetic resonance in cardiovascular diseases.- 70. B-Mode echography: A new approach to the epidemiology of atherosclerotic disease?.- 71. Cardiac doppler in the assessment of aortic valvular diseases.- 72. Myocardial ischemia in pediatric age: clinical pictures and non-invasive assessment.- 73. Extracranial carotid atherosclerosis evolution and stroke occurrence: Role of the echotomographic analysis.- 74. Pre- and post-operative echotomography and aortic endoarterectomy.